🔍

YATHARTH - Yatharth Hospit.

📊 NSE: YATHARTH 🏢 Healthcare 📅 Last Updated: 12/14/2025 15:20

📢 Recent Corporate Announcements

Yatharth Hospital Submits Q4 FY26 SEBI Reg 74(5) Compliance Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Apr 2026, 11:30 AM

Yatharth Hospital & Trauma Care Services Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited (the Registrar and Transfer Agent), confirms that securities received for dematerialization during the quarter ended March 31, 2026, were processed within prescribed timelines. It further verifies that physical security certificates were mutilated and cancelled after due verification. This is a standard administrative filing required for all listed companies in India to ensure the integrity of the dematerialization process.

Compliance certificate submitted for the quarter ended March 31, 2026.
Issued by Registrar and Transfer Agent MUFG Intime India Private Limited.
Confirms that dematerialized securities are listed on the relevant stock exchanges (NSE and BSE).
Verification and cancellation of physical certificates completed within prescribed timelines as per SEBI norms.

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor the company's quarterly financial results and operational performance.

Yatharth Hospital Seeks Shareholder Nod to Create Security on Assets up to ₹1,000 Crores

🟡 NEUTRAL ⭐ 6/10

FUNDRAISE 📅 09 Apr 2026, 11:58 AM

Yatharth Hospital has initiated a postal ballot to seek shareholder approval for creating charges, mortgages, or hypothecations on its assets. The special resolution, under Section 180(1)(a) of the Companies Act, 2013, proposes a limit of ₹1,000 crores to secure various debt instruments. This authorization will allow the company to secure term loans, debentures, and other credit facilities from banks and financial institutions. The move provides the board with the necessary flexibility to leverage company assets for future growth and operational funding.

Proposed limit for creation of security on movable and immovable assets is ₹1,000 crores.
Approval sought via special resolution under Section 180(1)(a) of the Companies Act, 2013.
Security to cover various instruments including Rupee loans, commercial papers, and foreign currency borrowings.
Remote e-voting period is scheduled from April 13, 2026, to May 12, 2026.
The resolution enables the board to secure both existing and future borrowings to support company undertakings.

💡 This is a standard enabling resolution that increases the company's capacity to secure debt for future requirements. Investors should monitor for subsequent announcements regarding specific expansion plans or capital expenditures that may utilize this ₹1,000 crore headroom.

Yatharth Hospital Trading Window to Close from April 1, 2026 for Q4 and FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Mar 2026, 03:36 PM

Yatharth Hospital & Trauma Care Services Limited has announced the closure of its trading window for all designated persons starting April 1, 2026. This closure is in compliance with SEBI Insider Trading regulations ahead of the declaration of audited financial results for the fourth quarter and full year ending March 31, 2026. The trading window will remain shut until 48 hours after the financial results are made public. The specific date for the Board Meeting to approve these results will be announced separately.

Trading window closure effective from April 1, 2026, for all designated persons and relatives.
Closure is related to the upcoming audited financial results for Q4 and FY ending March 31, 2026.
The window will reopen 48 hours after the official declaration of the financial results.
Board Meeting date for result approval to be intimated in due course of time.

💡 This is a routine regulatory announcement with no direct impact on business fundamentals; investors should wait for the Q4 result date announcement to assess financial performance.

Yatharth Hospital to Participate in DAM Capital Conference on March 23, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Mar 2026, 05:56 PM

Yatharth Hospital & Trauma Care Services Limited has announced its participation in the DAM Capital Hospitals and Diagnostics Conference. The event is scheduled for March 23, 2026, in Mumbai and is organized by DAM Capital Advisors Limited. This is a routine disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during the meeting.

Management to attend DAM Capital Hospitals and Diagnostics Conference on March 23, 2026
The event will take place in Mumbai and is hosted by DAM Capital Advisors Limited
Disclosure made in compliance with SEBI (LODR) Regulations, 2015
Company confirms no Unpublished Price Sensitive Information (UPSI) will be disclosed

💡 Investors should monitor the company's website for any post-event presentations or transcripts that may provide insights into the management's outlook on the hospital sector.

Yatharth Hospital Schedules Investor Visit to New Delhi and Faridabad Facilities on March 20

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Mar 2026, 06:18 PM

Yatharth Hospital & Trauma Care Services Limited has scheduled a visit for institutional investors and analysts on March 20, 2026. The visit is specifically focused on the company's newly operationalized hospital facilities located in New Delhi and Faridabad. This event is intended to help the investment community better understand the company's operational infrastructure and service capabilities. The company has explicitly stated that no unpublished price sensitive information will be shared during this visit.

Investor and analyst visit scheduled for Friday, March 20, 2026.
Focus on newly operationalized hospital units in New Delhi and Faridabad.
Purpose is to provide transparency regarding operations and facility infrastructure.
Compliance confirmed with no sharing of unpublished price sensitive information (UPSI).

💡 Investors should monitor for any subsequent analyst notes or reports that may provide qualitative insights into the efficiency and ramp-up of the new facilities. No immediate trading action is required based on this routine disclosure.

Yatharth Hospital Updates Authorized Personnel for SEBI Materiality Disclosures

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Feb 2026, 03:45 PM

Yatharth Hospital & Trauma Care Services Limited has updated its list of Key Managerial Personnel (KMP) authorized to determine the materiality of events under SEBI Regulation 30(5). The updated list includes 6 senior officials, including the Whole-time Director, CEO, and CFO. This administrative update supersedes previous authorizations and ensures the company remains compliant with listing obligations. The disclosure provides specific contact details for these officials to facilitate transparency and regulatory reporting.

Company authorized 6 senior officials to determine the materiality of events or information under SEBI guidelines.
Key personnel include Mr. Yatharth Tyagi (Whole-time Director), Mr. Amit Singh (CEO), and Mr. Pankaj Prabhakar (CFO).
The list also features Mr. Ashutosh Kumar Jha, Group Chief – Strategy, M&A and Investor Relations.
The update is a mandatory compliance requirement under Regulation 30(5) of SEBI (LODR) Regulations, 2015.
Centralized contact details for investor relations have been provided for these authorized personnel.

💡 No action is required as this is a routine administrative update. Investors can use the provided contact information for future inquiries regarding material company disclosures.

Yatharth Hospital Q3 FY26 Revenue Surges 46% YoY to INR 321 Cr; New Units Scale Rapidly

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 13 Feb 2026, 08:02 PM

Yatharth Hospital reported its highest-ever quarterly revenue of INR 3,205 million, marking a robust 46% YoY growth driven by existing facilities and a rapid scale-up of new hospitals in Delhi and Faridabad. The company achieved an adjusted EBITDA margin of 29.2% and a Net Profit of INR 431 million, up 41% YoY. Management highlighted that new facilities in Delhi and Faridabad Sector-20 contributed 9% to group revenue in their first full quarter with ARPOBs exceeding the group average. With the integration of the Agra hospital in February 2026 and a roadmap to reach 5,000 beds, the company maintains a strong growth trajectory.

Consolidated revenue grew 46% YoY to INR 3,205 million, with existing hospitals growing 33% YoY.
New Delhi and Faridabad Sector-20 hospitals generated INR 279 million in their first full quarter of operations.
Group ARPOB increased 10% YoY to INR 33,744, with Noida Extension reaching a record INR 44,000.
Net Profit (PAT) increased 41% YoY to INR 431 million, while adjusted PAT surged 80% YoY.
Maintains a strong balance sheet with a net cash position of approximately INR 200 crores as of December 31, 2025.

💡 Investors should monitor the successful integration of the Agra facility and the company's progress toward reducing government business mix to below 30%. The rapid breakeven of new units and aggressive expansion plans make it a high-growth contender in the regional healthcare space.

Yatharth Hospital Releases Audio Recording of Q3 FY26 Earnings Call

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 06 Feb 2026, 03:41 PM

Yatharth Hospital & Trauma Care Services Limited has officially released the audio recording of its Q3 FY26 earnings conference call. The call was conducted on February 06, 2026, following the announcement of financial results for the quarter ended December 31, 2025. This disclosure is part of the company's regulatory compliance under SEBI LODR Regulations. Investors can access the recording on the company's website to gain insights into management's discussion on operational performance and future guidance.

Earnings call for Q3 FY26 was held on February 06, 2026, at 1:00 PM IST.
Audio recording is now publicly available on the company's investor relations portal.
The call discussed performance for the nine-month period and quarter ended December 31, 2025.
Compliance filing made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 Investors should listen to the recording to understand management's outlook on bed occupancy rates and expansion plans. This is a routine administrative update and does not require immediate portfolio changes.

Yatharth Hospital Q3 FY26: Revenue Jumps 46% to ₹320 Cr, PAT Rises 41% to ₹43 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 04:18 PM

Yatharth Hospital delivered a strong performance in Q3 FY26, with revenue growing 46% YoY to ₹3,205 million and PAT increasing 41% to ₹431 million. Operational efficiency improved as occupancy reached 67% and ARPOB grew 10% to ₹33,744. The company successfully ramped up its new Delhi and Faridabad facilities, which contributed 9% to the total revenue. Additionally, the integration of the newly acquired 250-bed Agra hospital from February 2026 is expected to be immediately accretive to the bottom line.

Revenue grew 46% YoY to ₹3,205 mn and EBITDA increased 35% YoY to ₹742 mn in Q3 FY26.
Adjusted EBITDA margin (excluding new hospital ramp-up losses) stood at a robust 29.2%.
Occupancy improved to 67% from 56% YoY, while ARPOB increased 10% YoY to ₹33,744.
New Delhi and Faridabad Sec-20 hospitals generated ₹279 mn revenue in their first full quarter of operations.
Integrated a 250-bed Agra hospital on Feb 1, 2026, acquired for ₹260 Cr to expand the UP footprint.

💡 The stock remains a strong growth play in the healthcare sector given its successful M&A execution and rapid ramp-up of new beds. Investors should monitor the margin trajectory as new hospitals reach optimal utilization.

Yatharth Hospital Q3 FY26: Revenue Surges 46% YoY to Rs 321 Cr, PAT Up 41%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 02:17 PM

Yatharth Hospital reported a robust performance for Q3 FY26, with revenue growing 46% YoY to Rs 3,205 million and PAT increasing 41% to Rs 431 million. The growth was significantly bolstered by newly operational hospitals in New Delhi and Faridabad, which contributed 9% of total revenue in their first full quarter. While reported EBITDA margins dipped to 23.2% due to initial ramp-up costs, the adjusted EBITDA margin stood at a strong 29.2%. The company also achieved a 10% YoY improvement in Group ARPOB, reaching Rs 33,744.

Operating revenue grew 46% YoY to Rs 3,205 million, driven by a 33% growth in existing hospitals and new asset contributions.
New hospitals in New Delhi and Faridabad Sec-20 contributed Rs 279 million in revenue with 100% Cash/TPA payer mix.
Group ARPOB increased 10% YoY to Rs 33,744, with Noida Extension reaching a record high of Rs 44,000.
Adjusted EBITDA margin (excluding new hospital losses) stood at 29.2%, reflecting strong operating leverage.
Total bed capacity expanded to over 2,550 beds following the integration of the Agra facility in February 2026.

💡 Investors should note the company's exceptional ability to rapidly scale and turn around new acquisitions while maintaining high ARPOB growth. The stock remains a strong growth candidate in the healthcare sector given the successful integration of new assets and focus on high-margin payer mixes.

Yatharth Hospital Q3 Standalone Revenue Jumps 43% YoY to ₹158.1 Cr; Agra Hospital Acquired

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 02:02 PM

Yatharth Hospital reported a robust 43% YoY growth in standalone revenue to ₹158.15 crore for Q3 FY26. While Net Profit grew 7.4% YoY to ₹23.89 crore, the company showed strong sequential momentum with PAT rising 15.7% QoQ. The company continues its aggressive expansion, acquiring a 150-bed hospital in Agra effective February 2026. Additionally, the release of provisional attachments by the Income Tax department on company assets provides significant regulatory relief.

Standalone Revenue from operations grew 43% YoY to ₹1,581.5 million.
Standalone Profit After Tax (PAT) increased 7.4% YoY to ₹238.9 million.
Acquired Shantived Institute of Medical Sciences in Agra with 150 operational beds (expandable to 250).
Utilized ₹5,862.3 million of QIP proceeds for debt repayment, acquisitions, and medical equipment.
Income Tax department released provisional attachments on properties, bank deposits, and cash balances.

💡 Investors should view the strong revenue growth and inorganic expansion as positive indicators for long-term scale. Monitor the margin trajectory as the new Agra facility integrates and the pending tax appeal progresses.

Yatharth Hospital to Host Q3 FY26 Earnings Conference Call on February 6, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Feb 2026, 01:37 PM

Yatharth Hospital & Trauma Care Services has scheduled its Q3 FY26 earnings conference call for February 6, 2026, at 1:00 PM IST. The call follows the announcement of unaudited financial results for the quarter ended December 31, 2025. Senior management, including the Whole-Time Director, Group CEO, and Group CFO, will be present to discuss performance and outlook. The session is hosted by Nuvama Wealth Management and includes international dial-in options.

Earnings conference call scheduled for February 6, 2026, at 1:00 PM IST.
Focus on unaudited financial results for the quarter ended December 31, 2025.
Management representation includes the Whole-Time Director, Group CEO, and Group CFO.
International dial-in facilities available for investors in USA, UK, Singapore, and Hong Kong.

💡 Investors should monitor the Q3 results release on February 6th for key metrics like ARPOB and occupancy levels. Listening to the management commentary will provide clarity on the company's M&A strategy and expansion plans.

Yatharth Hospital Completes 100% Acquisition of Shantived Agra; Operations Start Feb 1

🟢 POSITIVE ⭐ 8/10

M&A 📅 29 Jan 2026, 01:27 PM

Yatharth Hospital has finalized the acquisition of a 100% stake in Shantived Institute of Medical Sciences, located in Agra, by executing a Share Purchase Agreement on January 29, 2026. This transaction follows the initial announcement made in September 2025 and marks a significant expansion of the company's footprint. Commercial operations at the newly acquired facility are scheduled to commence almost immediately on February 1, 2026. This rapid operationalization is expected to contribute to the company's revenue stream starting from the final quarter of the current fiscal year.

Executed Share Purchase Agreement (SPA) for the 100% acquisition of Shantived Institute of Medical Sciences, Agra.
The acquisition process was completed following the initial disclosure on September 13, 2025.
Commercial operations at the target hospital are set to begin on February 1, 2026.
The move strengthens the company's presence in the Uttar Pradesh healthcare market.

💡 Investors should monitor the occupancy rates and margin profile of the new Agra facility as it begins operations. The immediate start of commercial activities is a positive sign for near-term revenue growth.

Yatharth Hospital Reports Conversion of Statutory Auditor M S K A & Associates to LLP

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 20 Jan 2026, 10:52 AM

Yatharth Hospital & Trauma Care Services Limited has informed the exchanges that its statutory auditor, M S K A & Associates, has converted from a partnership firm to a Limited Liability Partnership (LLP). This change, effective from January 13, 2026, also applies to the company's material subsidiary, AKS Medical & Research Centre Private Limited. The firm will now be known as M S K A & Associates LLP with the updated ICAI registration number 105047W/W101187. This is a standard administrative conversion and does not represent a change in the auditing entity itself.

Statutory Auditor M S K A & Associates converted to an LLP effective January 13, 2026.
The conversion applies to both the parent company and its material subsidiary AKS Medical & Research Centre.
The new ICAI Firm Registration Number is 105047W/W101187.
The change is pursuant to the provisions of the Limited Liability Partnership Act, 2008.

💡 This is a routine administrative update regarding the legal structure of the auditor; no action is required from investors.

Yatharth Hospital Shareholders Approve Ramesh Krishnan as Independent Director with 92.76% Votes

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 17 Jan 2026, 04:56 PM

Shareholders of Yatharth Hospital & Trauma Care Services Limited have approved the appointment of Mr. Ramesh Krishnan as an Independent Director for a five-year term effective from November 5, 2025. The special resolution was passed via postal ballot with 92.76% of the total votes cast in favor. While the promoter group voted unanimously in favor, there was notable dissent from public institutional investors, with 34.02% of their votes cast against the resolution. The appointment is now finalized following the submission of the scrutinizer's report.

Special resolution passed with 92.76% majority, totaling 6,33,89,981 votes in favor.
Mr. Ramesh Krishnan appointed as Independent Director for a 5-year tenure ending November 4, 2030.
Significant dissent observed from public institutions, with 34.02% (49.43 lakh votes) voting against the appointment.
Promoter and promoter group cast 5.37 crore votes, representing 100% support for the resolution.
Total voter turnout represented 70.91% of the outstanding shares eligible to vote.

💡 Investors should note the successful board strengthening but may want to investigate the reasons behind the 34% institutional dissent regarding this specific appointment. No immediate portfolio changes are required as this is a routine governance update.

View All YATHARTH Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 31.3% YoY to INR 880.5 Cr in FY25. In Q2 FY26, revenue reached INR 279.4 Cr, up 28% YoY. Newer hospitals were the primary growth drivers with a 110% YoY increase, while mature hospitals sustained a 19% YoY upward trajectory.

Geographic Revenue Split

Highly concentrated in North India, specifically Delhi NCR and Madhya Pradesh. Eight out of nine hospitals are localized in this region, presenting a significant geographical concentration risk.

Profitability Margins

EBITDA margin stood at 25% in FY25. For Q2 FY26, the reported EBITDA margin was 23.1%, while the adjusted EBITDA margin (excluding initial losses from new units) was a healthy 26.7%. PAT margin for FY25 was 14.8%.

EBITDA Margin

EBITDA margin was 25% in FY25, a slight decrease from 26.8% in FY24. Q2 FY26 EBITDA stood at INR 64.5 Cr, up 18% YoY, though the margin compressed by 200 bps to 23.1% due to operationalizing new units.

Capital Expenditure

Planned capex of INR 400-450 Cr in FY26 for commencing operations at MGS and MD City. This is funded through a term loan of INR 200-220 Cr and surplus liquid funds from the December 2024 QIP.

Credit Rating & Borrowing

Credit rating upgraded to A/Stable. The company maintains a strong financial risk profile with a Debt/Equity ratio of 0.00 as of March 2025, following the prepayment of most borrowings using QIP proceeds.

⚙️ Operational Drivers

Raw Materials

Medical consumables, pharmacy supplies, and surgical implants represent the primary variable costs, included within operating expenses which totaled INR 660.2 Cr in FY25 (75% of revenue).

Capacity Expansion

Current operational beds increased to 1,185 in FY24. The company has an announced total capacity target of approximately 3,000 beds through greenfield and brownfield expansions.

Raw Material Costs

Operating expenses grew 34.5% YoY to INR 660.2 Cr in FY25, slightly outpacing revenue growth due to the addition of the Faridabad unit and increased specialized treatments.

Manufacturing Efficiency

Occupancy levels improved to 54% in FY24 from 45% in FY23. ARPOB increased 9% YoY to INR 25,080 in FY24, driven by specialized robotics and oncology treatments.

📈 Strategic Growth

Expected Growth Rate

30%

Growth Strategy

Achieving growth through geographic expansion in North India (Faridabad, Model Town, Agra), increasing occupancy at existing hospitals, and enhancing clinical excellence to drive higher ARPOB via oncology and robotics.

Products & Services

In-patient (IPD) and Out-patient (OPD) services, Radiation Oncology, Human Organ Transplant, Robotics Surgery, and Medical Value Travel (Medical Tourism).

Brand Portfolio

Yatharth Super Speciality Hospital.

New Products/Services

Introduction of radiation oncology, robotics surgery, and organ transplants, which contributed to the ARPOB increasing to INR 25,080.

Market Expansion

Strategic acquisitions in Faridabad, Model Town (Delhi), and Agra (Shantived) to broaden the healthcare network footprint.

Market Share & Ranking

Established market position in the Delhi NCR region with a strong brand recall and a track record of ~43% CAGR in operating income over three years.

🌍 External Factors

Industry Trends

The industry is shifting toward specialized, technology-driven care (robotics, oncology) and medical tourism. Yatharth is positioning itself as a high-end multi-specialty provider to capture this demand.

Competitive Landscape

Intense competition from large corporate hospital chains that have a pan-India presence compared to Yatharth's regional focus.

Competitive Moat

Moat is built on strong brand recall in North India, veteran leadership with 30+ years of experience, and high switching costs for patients requiring specialized, long-term treatments like oncology.

Macro Economic Sensitivity

Sensitive to inflation and fluctuating interest rates which present challenges to operational efficiency and financial stability.

Consumer Behavior

Increasing consumer preference for multi-specialty hospitals that offer comprehensive care under one roof, supporting the 54% occupancy rate.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to evolving healthcare regulatory frameworks and government-mandated pricing controls on certain medical procedures.

Taxation Policy Impact

Effective tax rate for Q2 FY26 was approximately 24.8% (INR 13.6 Cr tax on INR 54.8 Cr PBT).

Legal Contingencies

Received a favorable order from income tax authorities unfreezing provisional attached properties and fixed assets, restoring full financial flexibility for expansion.